Levosimendan (Q34257871)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Levosimendan	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

Levosimendan. (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Figgitt DP

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Gillies PS

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Goa KL

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

61

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

613-27; discussion 628-9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Site dependent bioavailability and metabolism of levosimendan in dogs

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The management of congestive heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Energetic aspects of inotropic interventions in rat myocardium

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myocardial efficiency during levosimendan infusion in congestive heart failure.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Haemodynamic dose-efficacy of levosimendan in healthy volunteers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers*

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of levosimendan and other calcium sensitizers

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of action of calcium-sensitizing drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levosimendan improves diastolic and systolic function in failing human myocardium.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of the contractile effects of levosimendan in the mammalian heart

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus recommendations for the management of chronic heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed?

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Troponin C–Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intracoronary levosimendan enhances contractile function of stunned myocardium

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular mechanisms of myocardial stunning

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of levosimendan on [Ca2+]i in guinea-pig isolated ventricular myocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/11368286

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200161050-00006

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34257871&oldid=2196432398"